6周与3个月的抗凝剂治疗对21岁以下因静脉血栓塞发作的患者的复发和出血事件的影响:儿童-DOTT随机临床试验
在PubMed上查看摘要
概括
此摘要是机器生成的。对于引起静脉血栓塞栓症的儿童和青少年,6周的抗凝药治疗时间与3个月的治疗时间一样安全和有效. 这种较短的治疗减少了出血风险,但没有增加复发风险.
科学领域
- 儿童血液学
- 心血管医学
- 临床试验
背景情况
- 儿童静脉血栓塞栓症 (VTE) 的最佳治疗持续时间尚未确定.
- 在21岁以下的患者中引起的静脉突发症需要进一步调查治疗时间.
研究的目的
- 为了确定6周的抗凝药治疗是否与21岁以下患者的3个月治疗不劣.
- 评估不同抗凝剂持续时间的复发性VTE和出血事件之间的权衡.
主要方法
- 这是一项随机临床试验,涉及42个国际中心的417名患有急性静脉瘤的儿童患者.
- 患者被随机分为6周或3个月的抗凝药治疗.
- 主要结局包括1年内出现症状性复发性静脉动脉突发症和临床相关出血事件,并对每项方案的人群进行非劣势性分析.
主要成果
- 在6周内,复发性静脉突发症的累积发病率为0. 66%,而在3个月内为0. 70%.
- 临床相关的出血发生率为6周的0. 65%和3个月的0. 70%.
- 与3个月组相比,6周组的不良事件较少 (26%) .
结论
- 在21岁以下的患者中,六周的抗凝药治疗与3个月的治疗无差.
- 较短时间的治疗表明VTE复发和出血风险之间的良好平衡.
- 这些发现支持在小儿引起的静脉动脉突发症中治疗时间更短.
相关概念视频
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
Nursing management begins with a thorough assessment of the patient's health history. Key factors include trauma to veins, peripherally inserted central catheters, varicose veins, recent pregnancy or childbirth, surgery, bacteremia, prolonged bed rest, atrial fibrillation, COPD, heart failure, cancer, coagulation disorders, myocardial infarction, spinal cord injury, stroke, prolonged travel, recent bone fractures, and dehydration. Review medication intake, particularly oral contraceptives,...
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...

